Objective: Many previous studies of drug repurposing have relied on literature review followed by evaluation of a limited number of candidate compounds.
| INTRODUCTION
A rare disease is defined by the U.S. Food and Drug Administration (FDA) Orphan Drug Act of 1983 as one affecting <200 000 individuals in the United States. Collectively, however, rare diseases affect >20 million people in the United States, reflecting 6%-7% of the population. The majority of these diseases are genetic, and only about 5% have an FDA-approved treatment. 1 Advances in sequencing technologies have helped to identify a growing number of genes linked to rare diseases, providing insight into the pathoetiologies of these disorders. Recently, there has been interest in developing treatments for genetic epilepsies by targeting underlying mechanisms. 2 Here, we adopt a precision medicine approach to identify potential candidate treatments for a patient with an epileptic encephalopathy caused by a mutation in SCN8A. SCN8A encodes the alpha subunit of the voltage-gated sodium channel, Na v 1.6, abundant in the peripheral and central nervous system (CNS), and found predominantly at the nodes of Ranvier.
3 Na v 1.6 helps regulate neuronal excitability through its unique location in the distal part of the axon initial segment, 4 its low voltage threshold for activation, 5 and its contribution to resurgent 6 and persistent 7 sodium-derived currents. Mutations in Na v 1.6 are estimated to account for 1% of epileptic encephalopathies. 8 The R1872 residue (GenBank NM_014191.3) is the most frequently reported site for disease-causing mutations in SCN8A, and cellular models have shown a gain-of-function phenotype caused by variants at this site. 9 We addressed the functional effects of an SCN8A de novo mutation where arginine is substituted for glutamine, R1872Q (NM_014191.3:c.5615G>A;p.R1872Q). This mutation was reported to cause a gain-of-function molecular phenotype involving excess sodium influx upon neuronal activation, resulting in hyperexcitability that may contribute to the epileptic encephalopathy clinical phenotype. 9 Therefore, inhibiting excess sodium influx into the cell could have specific therapeutic value by reducing neuronal hyperexcitability caused by this mutation. We characterized the SCN8A R1872Q mutant channel in a stably transfected HEK293 cell line, confirmed the gain-of-function phenotype, and carried out high-throughput drug screening using a fluorescent imaging plate reader (FLIPR) assay. We identified 90 compounds that significantly inhibited sodium influx into the cell from a chemical library of 1320 compounds that included clinically approved drugs and nutritional supplements. Three compounds appear to be promising therapeutic candidates based on their inhibitory activity, brain uptake, and safety profile: carvedilol (beta-blocker used to treat congestive heart failure), amitriptyline (serotonin-norepinephrine reuptake inhibitor antidepressant), and nilvadipine (calcium channel blocker used for hypertension). We confirmed, and further characterized, their inhibitory effects using electrophysiology in an HEK293 cellular model. These findings demonstrate the value of using personalized cellular models of a clinically relevant patient mutation to generate a clinically relevant platform for comprehensive drug repurposing effectiveness screening. This approach is conducive to identifying candidate treatments for patient-specific mutations manifesting as rare diseases, such as the infantile epileptic encephalopathies.
| MATERIALS AND METHODS

| HEK293 SCN8A cell line generation
The wild-type hSCN8A gene was polymerase chain reaction (PCR) amplified from human dorsal root ganglion and cloned into a mammalian expression retroviral vector under a cytomegalovirus promoter. The hSCN8A R1872Q variant (g5615a; CGG to CAG) was generated by site-directed mutagenesis (QuikChange II Site-Directed Mutagenesis kit; Agilent Technologies, Santa Clara, CA, USA). Plasmids containing wild-type SCN8A were used to establish a pool of control cells. Each stable pool was maintained in growth media containing 400 lg/mL G418 for selection. A clonal cell line expressing either wild-type SCN8A or R1872Q SCN8A was selected from dilution cloning and prioritized by functional sodium current amplitude using the IonWorks
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| 803 high-throughput electrophysiology platform (Molecular Devices, Sunnyvale, CA, USA). HEK293 cells expressing either wild-type or R1872Q SCN8A were cultured in Dulbecco modified Eagle medium/high glucose containing 10% fetal bovine serum, 2 mmolÁL -1 sodium pyruvate, 10 mmolÁL -1 hydroxyethylpiperazine ethane sulfonic acid (HEPES), and 400 lg/mL G418 at 37°C in the presence of 10% CO 2 . Cells were routinely passaged every 3-5 days to maintain <80% confluency. All studies were completed within cell passages 7-9. Upon reaching stable whole cell configuration, cells were held at a membrane potential of À120 mV, then depolarized in 10-mV increments from À120 mV to +60 mV. Each depolarizing step was applied for 500 milliseconds followed by a 20-millisecond step at 0 mV. The extracellular recording solution composition was (in mmolÁL -1 ): 135 The peak currents elicited by the D10-mV steps (500 milliseconds each) were used to calculate current-voltage relationships. To derive the conductance-voltage (GV) relationship, the calculated reversal potential of +72 mV was used such that conductance = current / (test potential À reversal potential). The peak currents from the second 0-mV (20 milliseconds) step were used to determine voltagedependent properties of steady-state inactivation (SSI) by plotting as a function of the D10-mV (500 milliseconds) prepulse voltage. Both GV and SSI curves were individually fit in GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) to the Boltzmann equation to derive the voltage at which 50% of the channels are in the inactivated state (V 1/2 ). Individual relationships were normalized such that fractional current = current amplitude/(fitted E max À fitted E min ). These normalized data were averaged, plotted as mean AE standard error of the mean values, and fit to the Boltzmann equation to yield 95% confidence intervals in addition to V 1/2 , slope, minimum, and maximum. Nonnormalized amplitudes were comparable between SCN8A wildtype and R1872Q clones.
| Quantitative PCR methods
F I G U R E 1 SCN8A R1872Q characterization. A,
| Compounds and reagents for FLIPR high-throughput screening
A library of 1320 small molecules was used for highthroughput screening (HTS). Most of the drugs were taken from the Prestwick Chemical Library (StrasbourgIllkirch, France), a collection of 1280 molecules comprised mostly of drugs approved by the FDA, European Medicines Evaluation Agency, and/or other agencies; additional compounds included sodium channel inhibitors and antiepileptic drugs (AEDs). The drug library was prepared as 10 mmolÁL -1 stocks in 100% dimethyl sulfoxide (DMSO) and diluted for use at 10 lmolÁL -1 .
Compounds were compressed from 96-well microplates into 384-well Echo LDV plates (Labcyte, San Jose, CA, USA). Lead compounds were obtained from independent suppliers and further characterized with concentrationresponse curves (CRCs) by adding 15 lL of 10 mmolÁL
compound stocks to 35 lL of DMSO. Serial dilutions were performed by transferring 25 lL of top compound concentration to 25 lL of DMSO and mixed. Dilutions were continued to generate a 10-point CRC. For AEDs and sodium channel inhibitors, 100 mmolÁL -1 compounds stocks were diluted for use at 300 lmolÁL -1 and serial dilutions were performed; the final DMSO concentration was 0.3%.
| FLIPR experiments
The day prior to screening, cells were harvested in growth media and plated on poly-D-lysine-coated, black-walled 384-well microplates with clear bottoms (Greiner Bio-One, Kremsm€ unster, Austria); 25 lL of a 0.9 9 10 6 cells per mL suspension were seeded into the plates. Plates were incubated at 37°C, 10% CO 2 overnight until used. Prior to testing, growth media were removed from the plate and R1872Q cell line. Concentration-dependent inhibition was observed for tetracaine, flecainide, and mexiletine (mean AE SEM, n = 4). C, Ten-point CRC of 2 known sodium channel toxins in the presence of 100 lmolÁL -1 veratridine using the Na v 1.6 R1872Q cell line. Concentrationdependent inhibition was observed for tetrodotoxin in the nmolÁL -1 range, whereas ProTx-II, a Na v 1.7 selective toxin, demonstrated minimal inhibitory activity and only at 300 lmolÁL
, the highest concentration tested (mean AE SEM, n = 4). RFU, relative fluorescence units
TEFLabs, Austin, TX, USA) was added (mixed with equal volume of 20% Pluronic F127). Cells were protected from light and incubated for 60-90 minutes at room temperature. After incubation, the dye was removed from the plates and replaced with 10 ll (in mM): 135 NaCl, 5. 
| PatchXpress protocol to assess pharmacological activity
Wild-type and mutant SCN8A cell lines were voltageclamped at a holding potential of À120 mV to maintain sodium channels in a closed resting state. After current amplitude became stable, the midpoint voltage of SSI was determined for each cell using a series of 5-second conditioning steps to increasingly depolarized voltages (À120 to À40 mV) that preceded a 20-millisecond test pulse to 0 mV to establish magnitude of inactivation. The holding command potential was then set to voltage at which 50% of the channels were in the inactivated state (V 1/2 -set automatically via PatchXpress scripts). From this holding potential, a 2-millisecond voltage step to holding potential followed by a 20-millisecond depolarizing step to 0 mV and then 2 seconds at the holding potential were applied at a frequency of 0.1 Hz until current amplitude was steady (automatically determined by PatchXpress scripts), at which time a test compound was added. The effect of test reagents on Na v current amplitude was monitored using the voltage protocol described above, and washed out after reaching steady-state as determined by PatchXpress stability scripts. Data were collected on a PatchXpress platform using Patch Commander Software (Molecular Devices), then processed and analyzed using DataXpress 2.0 (Molecular Devices). Percentage inhibition was normalized to the average of the control and washout currents according to the formula: % Inhibition = ([Ctrl + Wash] / 2) À Drug/([Ctrl + Wash] / 2) 9 100. Normalized concentration-response relationships were fitted using the XLfit software (ID Business
where A = assay min (fixed at 0%), B = assay max (fixed at 100%), C = IC 50 , and D = slope.
| RESULTS
| Clinical description and variant identification
The patient (female, 11 years old) was diagnosed with epilepsy and global developmental delay consistent with type 13 early infantile epileptic encephalopathy (EIEE13). She is nonverbal. The patient can walk <10 feet with assistance and ankle-foot orthoses. Her first afebrile seizure occurred at 3 months. Seizure types in the past have included atypical absence, myoclonic, tonic, and tonic-clonic head drops. The epilepsy was resistant to more than 10 AEDs and several immunomodulatory therapies, but did respond to carbamazepine.
When the child was 8 years old, a medical laboratory with clinical pathology accreditation (London, UK) identified the presence of a heterozygous c.5615G>A; p.R1872Q SCN8A variant in the patient's DNA through next generation sequencing of 66 genes associated with severe developmental delay; the result was confirmed by Sanger sequence analysis. Parental analysis of lymphocyte DNA did not identify the mutation, consistent with a de novo origin in the child. The R1872Q mutation encoded by the SCN8A gene was classified as pathogenic with reference to a previous report that identified a different mutation in the SCN8A gene (L1290V) associated with epileptic encephalopathy. 10 Subsequently, Wagnon et al 9 reported on a male patient with the identical R1872Q SCN8A mutation that was associated with EIEE13.
3.2 | Generation and characterization of the wild-type and Na v 1.6 R1872Q variant cell lines
To assess the mutation in a cellular model that would be amenable to HTS, we used the HEK293 cell line, an immortalized human cell line utilized extensively for ion channel physiology experiments and HTS studies. 11 We used site-directed mutagenesis to introduce the R1872Q variant (g5615a; CGG to CAG) into the SCN8A cDNA, and then transfected a plasmid containing the mutated cDNA into HEK293 cells and generated a stable clonal Na v 1.6 R1872Q cell line. Sequence integrity of the expressed construct in each cell line was confirmed using reverse transcriptase (RT)-PCR and sequencing of the resulting cDNA. A wild-type SCN8A stable clonal cell line was also generated for control purposes.
We then functionally characterized and compared the Na v 1.6 R1872Q variant and Na v 1.6 wild-type cell lines using electrophysiology. Current-voltage plots were obtained by applying test pulses at membrane potentials between À100 mV and +60 mV ( Figure 1A,B) . The fractional GV relationship for Na v 1.6 R1872Q channel activation revealed a significant 4.7 mV leftward shift in V 1/2 compared to wild-type channels (À30.3 AE 0.7 mV, n = 10 for Na v 1.6 R1872Q and À25.6 AE 0.7 mV, n = 12 for Na v 1.6 wild-type, P < .05; Figure 1C ). These data confirm findings from prior studies on the same mutation. 9 We also investigated the voltage dependence of steady-state inactivation, finding no significant difference between cells bearing mutant or wild-type channels ( Figure 1C ). There was a small increase in the window current largely due to the leftward shift in voltage dependent activation as noted above ( Figure 1C ). Inactivation kinetics were studied at a test potential of 0 mV ( Figure 1D ). The decay phase was best fit by a single exponential. A significantly delayed rate of inactivation was found in Na v 1.6 R1872Q channels compared with Na v 1.6 wild-type channels (P < .05; Figure 1D ). The measured time constant for inactivation was significantly slower for the Na v 1.6 R1872Q variant than the wild-type (s inactivation: 0.7 AE 0.1 milliseconds, n = 15 for R1872Q and 0.4 AE 0.05 milliseconds, n = 11 for wild-type, P < .05; Figure 1E ). We did not see an elevated persistent F I G U R E 3 Screening results from the 1320-compound library for inhibitory activity against the R1872Q SCN8A sodium channel. The histogram shows the number of screened drugs at each given level of inhibition (5%/bin). The bins in light blue represent compounds with inhibitory activity > 2 standard deviations (SD; ≥63.0%) above the group mean (10.8%). A total of 90 compounds met or exceeded this level of inhibitory activity and were defined as hits in the assay. See Table 1 for a complete list of compounds and activity T A B L E 1 High-throughput screening results: compounds with significant inhibitory activity against SCN8A sodium channels at 10 lmolÁL -1
Chemical name
Inhibition, % current at a test potential of 0 mV in the Na v 1.6 R1872Q line. These data also confirm findings from previous studies. 9 
| Screening of a library of approved drugs
We utilized a stimulus-activated, fluorescence-based Na + flux assay with an FLIPR high-throughput cellular screening system. 11 Fluorescence-based screening assays are frequently used for assessing ion channel function. 12, 13 After preincubation with the Na + indicator dye, ANG-2, clonal cell lines were tested for their abilities to generate a fluorescent readout in response to veratridine, a neurotoxin that causes persistent opening of sodium channels. Veratridine CRCs were generated using the Na v 1.6 R1872Q clonal cell line, revealing a robust dynamic range (Figure 2A ) consistent with historical data generated on wild-type Na v 1.6 channels and suitable for screening. 14 The ability to detect a concentration-dependent reduction in sodium flux was demonstrated using known sodium channel inhibitors including tetracaine, flecainide, and mexiletine ( Figure 2B ). The pharmacology of expressed Na v 1.6 sodium channels toward channel-specific inhibitors was also evaluated. Cells demonstrated sensitivity to tetrodotoxin, which inhibits voltage-gated sodium channels except Na v 1.5, Na v 1.8, and Na v 1.9, and lack of activity of the tarantula venom peptide, ProTx-II, which is a selective inhibitor of Na v 1.7 channels ( Figure 2C ). 15 We then initiated screening of a library of 1320 pharmacologically diverse drugs (including the Prestwick Chemical Library of 1280 compounds) at 10-lmolÁL -1 concentration; compounds were evaluated in duplicate. A set concentration of 10 lmolÁL -1 was considered to be suitable to identify compounds with a level of potency and effectiveness in the in vitro screen that might translate to pharmacological activity in vivo. Z-prime values were >0.5, signifying a robust, tetracaine (100%) and DMSO (0%) controls. The average inhibition for the entire library was 10.8%. Ninety compounds showed >2 standard deviation inhibition (≥63.0%) from the mean ( Figure 3A) ; the majority of these have not been previously linked to sodium channels, in particular with activity against Na v 1.6, or other ion channel activity in general. This group of 90 compounds was then screened a second time using independently sourced drugs at 10 lmolÁL
to confirm activity in the assay. The complete list of 90 hit compounds along with inhibitory activity is shown in Table 1 .
| Comparison to traditional pharmacological agents
We sought to further assess the response of both the Na v 1.6 R1872Q and Na v 1.6 wild-type lines to 24 AEDs using CRCs (10 points, 10 nmolÁL -1 to 300 lmolÁL -1 , n = 4 across 2 separate trials). Drugs were tested in both the Na v 1.6 R1872Q and wild-type Na v 1.6 cellular models. Across a full CRC, several AEDs showed strong inhibition of both channels (eg, clonazepam), whereas the majority were far less effective, even at relatively high drug concentrations of 300 lmolÁL -1 (Table 2) . We also generated CRCs for 10 known sodium channel inhibitors in wild-type and Na v 1.6 R1872Q cell lines. Most compounds demonstrated a moderate level of activity with a trend for greater F I G U R E 4 Electrophysiological characterization of lead compounds. Graphs show concentration-dependent current inhibition (%) of Na v 1.6
wild-type (black circles) and Na v 1.6 R1872Q (red squares) channels for amitriptyline, carvedilol, nilvadipine, and carbamazepine. Five-point concentration-response curves (n ≥ 4 for each data point) were generated for all 4 test compounds on wild-type and Na v 1.6 R1872Q variants. inhibitory potency on the Na v 1.6 wild-type cell line compared to the Na v 1.6 R1872Q cell line (Table 3) .
| Electrophysiological evaluation of select compounds
To further explore the activity of compounds that demonstrated strong inhibitory effects in the FLIPR screen, we evaluated 3 lead compounds, amitriptyline, carvedilol, and nilvadipine, in an electrophysiological assay, along with carbamazepine; a well-known sodium channel blocker and an AED with demonstrated clinical benefit in the SCN8A R1872Q patient. The inhibitory effect of these compounds was assessed using the PatchXpress automated electrophysiological platform, with Na v 1.6 R1872Q and wild-type cell lines held at the midpoint voltage of SSI. Peak currents in response to a depolarizing pulse were measured across a 5-point CRC, which confirmed a strong inhibitory effect of the test compounds in a concentration-dependent manner ( Figure 4 ). The IC 50 values for Na v 1.6 wild-type and Na v 1.6 R1872Q were determined from the CRCs and showed the same trend for greater potency of effect on the wild-type over mutant channel as was noted above with AEDs (Table 2 ) and sodium channel inhibitors (Table 3) .
| DISCUSSION
Our study confirms the utility of a high-throughput functional assay to comprehensively evaluate approved medicines to identify potential targeted treatments that could be available for immediate clinical use. This work shows that at least for a sodium channel with a clear gain-of-function mutation, a comprehensive drug repurposing screen is both feasible and effective. The present study suggests that testing only one or a few candidate drugs to identify a potential repurposed treatment for a genetic condition provides too limited a picture of the potential drug opportunities that could be therapeutically evaluated. When translating findings from cellular assays to therapeutic use, it is essential to consider whether concentrations required for in vitro activity are physiologically relevant to prescribed clinical doses. To that end, we compared the drug concentrations of our lead compounds, amitriptyline, nilvadipine, and carvedilol, as well as carbamazepine, required to inhibit Na v 1.6 R1872Q sodium channel activity in vitro, to published data on CNS drug concentrations from standard oral clinical doses. Carbamazepine has an average brain concentration of 3.52 lmolÁL -1 over a variety of doses when unbound fraction and brain penetrance are taken into account. 16, 17 Relating that CNS level to the data generated with our electrophysiological evaluation ( Figure 4) correlates to 4.7% inhibition against the Na v 1.6 R1872Q channel and 9.6% inhibition against the wild-type ion channel with clinical doses. When carvedilol is taken at a 100-mg daily dose (50 mg, twice daily), a steady-state maximum plasma concentration of 205 ng/mL (0.50 lmolÁL -1 ) is reached within 1.5 hours. 18 Carvedilol penetrates the blood-brain barrier, resulting in an estimated average CNS concentration of 0.15 lmolÁL -1 . 19 The steady-state free brain concentrations would therefore correspond to an inhibition of 5.6% and 7.4% against the mutant and the wild-type channels, respectively, which is similar to carbamazepine. Likewise, nilvadipine, a calcium blocker used to treat hypertension, reaches a steady-state maximum plasma concentration of 11.7 ng/mL with 16 mg taken daily. 20 The concentration that reaches the brain, roughly 0.05 lmolÁL -1 , 21 would correspond to 1.3% inhibition against the mutant and 0.4% against the wild-type according to the CRCs, which is lower than predicted values for carbamazepine. Amitriptyline is an effective antidepressant at steady-state plasma concentrations at 150-250 ng/mL. 22 Although data on brain levels of amitriptyline following chronic dosing are somewhat limited, studies in rodents suggests levels can reach 5-7 lmolÁL -1 . 23 From the present study, amitriptyline at this concentration would correspond to a 59% to 84% inhibition of Na v 1.6 channels based on results from the electrophysiological assay ( Figure 4) . Whereas nilvadipine has not been previously reported to act on sodium channels, both amitriptyline and carvedilol are known to inhibit sodium channels in a use-dependent manner. 24, 25 Amitriptyline has high affinity for both open and inactivated channels, but low affinity for resting state channels. 26 Binding to the open and inactivated channel states is also a common feature of AEDs, 27 allowing for preferential inhibition of high-frequency repetitive firing neurons during seizures with more limited impact on normal brain activity. 28 Precise mechanisms of binding and how these 3 inhibitors affect the Na v 1.6 contribution to resurgent and persistent sodium-derived currents in neurons remain to be investigated. 6, 7 Nevertheless, this work identified interesting drug candidates for further investigation, especially amitriptyline, which was shown to be a potent inhibitor of Na v 1.6. Although the way SCN8A mutations cause disease in vivo cannot be fully captured in an in vitro heterologous expression system, the active compounds we identified through HTS represent important candidates for further characterization in appropriate in vivo models, and for subsequent design of new chemical entities.
Identifying viable candidates from an extensive library of clinically approved drugs that directly inhibit a gain-offunction pathogenic mutation illustrates the feasibility and potential of comprehensive drug repurposing screening to identify new therapeutic options for serious genetic conditions. Comparing estimated CNS exposure at clinically established doses of a drug with assay inhibitory activity provides an opportunity for more informed selection of therapeutically meaningful treatment decisions in affected patients.
